VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for VORANIGO, the first targeted therapy developed specifically for patients with IDH-mutant diffuse glioma.